<DOC>
	<DOCNO>NCT01109927</DOCNO>
	<brief_summary>Among adult patient diagnose type 2 diabetes , 6 % autoantibody direct insulin produce beta cell pancreas . These patient progressive beta cell destruction insulin dependent within 3-5 yr . Patients latent autoimmune diabetes adult ( LADA ) considerable remain beta cell mass diagnosis , suitable evaluate new therapy autoimmune diabetes Animal study diabetes prone mouse demonstrate potential positive effect early insulin treatment , low incidence diabetes delay diagnosis . The aim study investigate effect early insulin treatment LADA patient , respect residual beta-cell function metabolic control , compare group conventionally treat diet and/or oral hypoglycaemic agent ( OHA ) insulin clinically need .</brief_summary>
	<brief_title>Early Insulin Treatment Patients With Latent Autoimmune Diabetes</brief_title>
	<detailed_description>All adult newly diagnose diabetic patient certain area screen pancreatic antibody . Patients clinically classify Type 2 , insulin require diagnosis positive least one autoantibody eligible inclusion . After randomisation insulin treatment diet and/or OHA , patient follow fasting C-peptide every third month . A glucagon test perform , stimulate C-peptide HbA1c , + clinical data body weight record baseline 12 , 24 36 month . The final outcome study C-peptide , change C-peptide compare baseline level , HbA1c , 36 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>&gt; 18 yr Positive pancreatic autoantibody &lt; 18 yr Significant concomitant diseases Not able follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 1995</verification_date>
</DOC>